

Alexandria P Cogdill

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1877297/alexandria-p-cogdill-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29 papers	9,977 citations	23 h-index	30 g-index
30 ext. papers	13,025 ext. citations	22 avg, IF	5.32 L-index

#	Paper	IF	Citations
29	Hallmarks of Resistance to Immune-Checkpoint Inhibitors.. <i>Cancer Immunology Research</i> , 2022 , 10, 372-383	33.5	2
28	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.. <i>Science</i> , 2021 , 374, 1632-1640	33.3	52
27	Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. <i>Cell</i> , 2021 , 184, 5338-5356.e21	56.2	37
26	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021 , 27, 1432-1441	50.5	57
25	The human tumor microbiome is composed of tumor type-specific intracellular bacteria. <i>Science</i> , 2020 , 368, 973-980	33.3	379
24	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020 , 577, 549-555	50.4	654
23	Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors. <i>Onc Immunology</i> , 2020 , 9, 1794423	7.2	3
22	Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 22699-22709	11.5	119
21	The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies. <i>Annals of Surgical Oncology</i> , 2018 , 25, 1814-1827	3.1	30
20	Interaction between Targeted Therapy and Immunotherapy 2018 , 268-285		
19	Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. <i>Science</i> , 2018 , 359, 97-103	33.3	1895
18	Checkpoint Blockade Reverses Anergy in IL-13R α Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas. <i>Molecular Therapy - Oncolytics</i> , 2018 , 11, 20-38	6.4	70
17	The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy. <i>Trends in Immunology</i> , 2018 , 39, 900-920	14.4	36
16	Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. <i>Nature</i> , 2018 , 558, 307-312	50.4	362
15	Gene Targeting Meets Cell-Based Therapy: Raising the Tail, or Merely a Whimper?. <i>Clinical Cancer Research</i> , 2017 , 23, 327-329	12.9	1
14	Hallmarks of response to immune checkpoint blockade. <i>British Journal of Cancer</i> , 2017 , 117, 1-7	8.7	138
13	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. <i>Npj Genomic Medicine</i> , 2017 , 2,	6.2	82

12	Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. <i>Cell</i> , 2017 , 170, 1120-1133.e17	56.2	659
11	Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. <i>Immunity</i> , 2016 , 44, 1444-54	32.3	338
10	Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. <i>Blood</i> , 2016 , 127, 1117-27	2.2	282
9	Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. <i>Cancer Research</i> , 2015 , 75, 3596-607	10.1	298
8	Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. <i>Science Translational Medicine</i> , 2015 , 7, 275ra22	17.5	301
7	BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. <i>Clinical Cancer Research</i> , 2013 , 19, 1225-31	12.9	679
6	Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer. <i>Surgery</i> , 2013 , 154, 1456-62; discussion 1462	3.6	19
5	Targeting the MAGE A3 antigen in pancreatic cancer. <i>Surgery</i> , 2012 , 152, S13-8	3.6	16
4	EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. <i>Cancer Discovery</i> , 2012 , 2, 227-35	24.4	663
3	COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. <i>Nature</i> , 2010 , 468, 968-72	50.4	1162
2	Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. <i>Cancer Research</i> , 2010 , 70, 5213-9	10.1	562
1	Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. <i>Blood</i> , 2009 , 114, 535-46	2.2	1077